See more : 450 Plc (450.L) Income Statement Analysis – Financial Results
Complete financial analysis of Tissue Regenix Group plc (TSSNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tissue Regenix Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Park Lawn Corporation (PRRWF) Income Statement Analysis – Financial Results
- SHUAA Partners Acquisition Corp I (SHUAU) Income Statement Analysis – Financial Results
- Shanghai Highly (Group) Co., Ltd. (600619.SS) Income Statement Analysis – Financial Results
- Armada Mercantile Ltd. (AAMTF) Income Statement Analysis – Financial Results
- Pegroco Invest AB (publ) (PEGRO-PREF.ST) Income Statement Analysis – Financial Results
Tissue Regenix Group plc (TSSNF)
About Tissue Regenix Group plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.
Source: https://incomestatements.info
Category: Stock Reports